TriSalus Life Sciences Inc. guided investors to $60-$62 million in 2026 revenue on March 5, then slashed that outlook to $54-$57 million months later

Shareholders who held TriSalus Life Sciences Inc. (TLSI) stock lost money after the company cut its full-year 2026 revenue guidance to $54 million-$57 million, down from the $60 million-$62 million range reaffirmed approximately two months earlier on March 5, 2026. Those who purchased TLSI shares and suffered losses are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

On March 5, 2026, during the Q4 2025 earnings call, CEO Mary Szela stated: "Based on our performance in 2025 and our visibility entering 2026, we are reaffirming our revenue guidance of $60 million to $62 million." On the same call, Szela told investors: "Importantly, this cadence should not be interpreted as a change in underlying demand trends." Months later, the company reported Q1 2026 revenue of $8.9 million against consensus estimates of $9.4 million -- and cut full-year guidance by as much as $8 million from the high end of the prior range.

The $60-$62 million reaffirmation was issued on March 5, 2026. The $54-$57 million revised outlook followed approximately two months later.

If you lost money on a TLSI investment, click here to discuss your legal rights with Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com

Frequently Asked Questions About the TLSI Investigation

Q: Who is eligible to participate in the TLSI investigation? A: Investors who purchased TLSI stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether TriSalus Life Sciences made materially false or misleading statements regarding its 2026 revenue outlook, including the March 5, 2026 reaffirmation of $60 million-$62 million in full-year revenue guidance. When the company subsequently cut that guidance to $54 million-$57 million, the stock price declined sharply.

Q: What do TLSI investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What if I already sold my TLSI shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TLSI and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260519640354/en/